Xgene

Xgene Pharmaceutical is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for pain management and inflammatory diseases. The company's pipeline features several small molecule candidates, including XG005, a first-in-class dual-acting agent targeting both COX-2 and sodium channels for the treatment of acute and chronic pain. Xgene operates with a global footprint, maintaining research and development facilities in both China and the United States. By leveraging its expertise in medicinal chemistry and pain biology, the company aims to provide safer and more effective alternatives to traditional opioids and NSAIDs. Their lead programs are currently progressing through clinical trials to address significant unmet needs in postoperative and neuropathic pain.